



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Factors Affecting the Outcome in Moderate and Severe COVID-19 in Geriatric Quarantine Hospital at Ain Shams University

Thesis

*Submitted For Partial Fulfillment of Master Degree
In Geriatrics and Gerontology*

By

Sara Farrag Mohammed

M.B.B.CH.

Supervised by

Prof. Dr. Somaia Mohamed Ebeid

*Professor of Geriatrics and Gerontology
Faculty of Medicine, Ain Shams University*

Dr. Doha Rasheedy Ali

*Assistant Professor of Geriatrics and Gerontology
Faculty of Medicine, Ain Shams University*

Dr. Dina Mostafa El Maleh

*Lecturer of Geriatrics and Gerontology
Faculty of Medicine, Ain Shams University*

Dr. Nesma Gamal El Sheikh

*Lecturer of Geriatrics and Gerontology
Faculty of Medicine, Ain Shams University*

Faculty of Medicine - Ain Shams University

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and
profound gratitude to **Prof. Dr. Somaia
Mohamed Ebeid**, Professor of Geriatrics and
Gerontology - Faculty of Medicine- Ain Shams
University for her keen guidance, kind supervision,
valuable advice and continuous encouragement, which
made possible the completion of this work.*

*I am also delighted to express my deepest
gratitude and thanks to **Dr. Doha Rasheedy Ali**,
Assistant Professor of Geriatrics and Gerontology,
Faculty of Medicine, Ain Shams University, for her kind
care, continuous supervision, valuable instructions,
constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Dina Mostafa
El Maleh**, Lecturer of Geriatrics and Gerontology,
Faculty of Medicine, Ain Shams University, for her great
help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to
Dr. Nesma Gamal El Sheikh, Lecturer of
Geriatrics and Gerontology, Faculty of Medicine, Ain
Shams University, for her kindness, supervision and
cooperation in this work.*

*I would like to express my hearty thanks to all my
family for their support till this work was completed.*

*Last but not least my sincere thanks and
appreciation to all patients participated in this study.*

Sara Farrag Mohammed

List of Contents

Title	Page No.
List of Tables	i
List of Figures.....	iii
List of Abbreviations.....	v
Introduction.....	1
Aim of the Work.....	3
☞ SARS-COV-2: Virology, Epidemiology, and Clinical Features.....	4
☞ COVID 19 Diagnosis, Complications, and Predictors of Mortality.....	34
☞ Treatments and Vaccines for COVID-19.....	59
Subjects and Methods.....	82
Results.....	88
Discussion.....	129
Summary	152
Conclusion.....	157
Limitation of the Study.....	158
Recommendations.....	159
References	160
Arabic Summary.....	١

List of Tables

Table No.	Title	Page No.
Table (1):	Baseline characteristics of the three groups:	89
Table (2):	The prevalence of different presenting symptoms and signs at admission among the three groups:.....	91
Table (3):	The prevalence of comorbidities among the three groups:	96
Table (4):	COVID 19 related complications among the three groups:.....	97
Table (5):	Chest CT findings among the participants:	103
Table (6):	Prognostic markers among the three groups:.....	104
Table (7):	Admission CBC parameters among different groups:.....	105
Table (8):	Lymphocytic count on admission among different groups:	106
Table (9):	Hemoglobin status on admission among different groups:	107
Table (10):	Platelet count on admission among different groups:.....	108
Table (11):	ROC curves of different laboratory markers in predicting mortality	115
Table (12):	Antiviral drugs usage in different groups:	116
Table (13):	The use of antiplatelets and anticoagulants among the studied groups:	117
Table (14):	The use of anti-inflammatory among groups:.....	119
Table (15):	The use of Tocilizumab among groups:	122
Table (16):	The descriptive analysis of cases received convalescent plasma therapy:.....	124

List of Tables (Cont...)

Table No.	Title	Page No.
Table (17):	Anti-inflammatory drugs and relation with the outcome:	125
Table (18):	The use of mechanical ventilation in different groups:	126
Table (19):	The patients' outcomes according to age groups:.....	127
Table (20):	Logistic regression of predictors of mortality:.....	128

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Diagram of the SARS-COV-2 virion particle	8
Figure (2):	Schematic representation for SARS-COV-2 attachment and entry into airway cells	13
Figure (3):	Multiple large patchy GGOs appear in both lungs with consolidations containing air bronchogram inside and obvious thickening of interlobular septum	38
Figure (4):	Examples of the chest X-ray scoring system in two patients with COVID-19 pneumonia	39
Figure (5):	Severity of COVID 19 illness among the three groups	90
Figure (6):	Different presenting symptoms and signs	92
Figure (7a):	The distribution of fever as a presenting symptom in different groups	93
Figure (7b):	The distribution of cough as a presenting symptom in different groups	93
Figure (7c):	The distribution of dyspnea as a presenting symptom in different groups	94
Figure (7d):	The distribution of DLOC as a presenting symptom in different groups	94
Figure (7e):	The distribution of hypoxia as a presenting symptom in different groups	95
Figure (7f):	The distribution of severe respiratory distress as a presenting symptom in different groups	95
Figure (8):	COVID-19 related complications	98
Figure (9a):	The distribution of respiratory failure complicating COVID 19 in the three groups	98
Figure (9b):	The distribution of ARDS complicating COVID 19 in the three groups	99
Figure (9c):	The distribution of diabetic emergency complicating COVID 19 in the three groups	99
Figure (9d):	The distribution of confusion complicating COVID 19 in the three groups	100

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (9e):	The distribution of acute stroke complicating COVID 19 in the three groups.....	100
Figure (9f):	The distribution of shock complicating COVID 19 in the three groups.....	101
Figure (9g):	The distribution of AKI complicating COVID 19 in the three groups.....	101
Figure (9h):	The distribution of psychiatric illness complicating COVID 19 in the three groups.....	102
Figure (10):	Total leucocytic count on admission in different groups.	109
Figure (11):	Serum hemoglobin concentration on admission in different groups	109
Figure (12):	Platelet count on admission in different groups.	110
Figure (13a):	ROC curve for IL 6 for predicting mortality in the studied sample.....	111
Figure (13b):	ROC curve for albumin for predicting mortality in the studied sample.....	111
Figure (13c):	ROC curve for ALT for predicting mortality in the studied sample.....	112
Figure (13d):	ROC curve for D dimer for predicting mortality in the studied sample.....	112
Figure (13e):	ROC curve for ferritin for predicting mortality in the studied sample.....	113
Figure (13f):	ROC curve for CRP for predicting mortality in the studied sample.....	113
Figure (13g):	ROC curve for LDH for predicting mortality in the studied sample.....	114
Figure (13h):	ROC curve for lymphocytes for predicting mortality in the studied sample	114
Figure (14):	The use of antiplatelets in different groups	118
Figure (15):	The use of anticoagulants in different groups	118
Figure (16):	Days of onset of steroid therapy in all cases	121
Figure (17):	Days of onset of tocilizumab therapy.....	123

List of Abbreviations

Abb.	Full term
<i>ACE2</i>	<i>Angiotensin converting enzyme 2</i>
<i>ACS</i>	<i>Acute coronary syndrome</i>
<i>Ad26</i>	<i>Adenovirus type 26</i>
<i>AEs</i>	<i>Adverse events</i>
<i>AKI</i>	<i>Acute kidney injury</i>
<i>AMI</i>	<i>Acute mesenteric ischemia</i>
<i>APC</i>	<i>Antigen-presenting cells</i>
<i>ARDS</i>	<i>Acute respiratory distress syndrome</i>
<i>AZ</i>	<i>AstraZeneca</i>
<i>AZ</i>	<i>Azithromycin</i>
<i>BAL</i>	<i>Bronchoalveolar lavage</i>
<i>BiPAP</i>	<i>Bilevel positive airway pressure</i>
<i>CCP</i>	<i>COVID-19 convalescent plasma</i>
<i>CDC</i>	<i>Centers for Disease Control and Prevention</i>
<i>CEPI</i>	<i>Coalition for Epidemic Preparedness Innovations</i>
<i>CFR</i>	<i>Case fatality rate</i>
<i>CKD</i>	<i>Chronic kidney disease</i>
<i>COPD</i>	<i>Chronic obstructive pulmonary diseases</i>
<i>COVID-19</i>	<i>Coronavirus disease 2019</i>
<i>CPAP</i>	<i>Continuous positive airway pressure</i>
<i>CPT</i>	<i>Convalescent plasma therapy</i>
<i>CRF</i>	<i>Case record form</i>
<i>CRP</i>	<i>C- Reactive Protein</i>
<i>CSVT</i>	<i>Cerebral sinus vein thrombosis</i>
<i>CT</i>	<i>Computed tomography</i>
<i>cTnI</i>	<i>Cardiac troponin</i>
<i>CVD</i>	<i>Cardiovascular disease</i>
<i>CVS</i>	<i>Central nervous system</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>CVST</i>	<i>Cerebral venous sinus thrombosis</i>
<i>DAIDS</i>	<i>DAIDS Division of AIDS</i>
<i>DIC</i>	<i>Disseminated intravascular coagulation</i>
<i>DOAC</i>	<i>Direct Oral Anticoagulant</i>
<i>ECMO</i>	<i>Extracorporeal membrane oxygenation</i>
<i>ELISA</i>	<i>Enzyme linked immunosorbent assay</i>
<i>EUAs</i>	<i>Emergency Use Authorizations</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>GBS</i>	<i>Guillain-Barre syndrome</i>
<i>GGO</i>	<i>Ground-glass opacity</i>
<i>GI</i>	<i>Gastrointestinal</i>
<i>HCQ</i>	<i>HydroxyChloroquine</i>
<i>HE</i>	<i>Hemagglutinin-esterase</i>
<i>HFNC</i>	<i>High flow nasal cannula</i>
<i>HFNO</i>	<i>High-flow nasal oxygen</i>
<i>HIT</i>	<i>Heparin-induced thrombocytopenia</i>
<i>HIV</i>	<i>Human immunodeficiency virus</i>
<i>HSPGs</i>	<i>Heparan Sulfate Proteoglycans</i>
<i>ICH</i>	<i>Intracerebral hemorrhage</i>
<i>ICUs</i>	<i>Intensive care units</i>
<i>IFA</i>	<i>Immune fluorescent assay</i>
<i>IFN-α</i>	<i>interferon α</i>
<i>IL-1</i>	<i>Interleukin -1</i>
<i>IL-6</i>	<i>Interleukin-6</i>
<i>IMP</i>	<i>Importin</i>
<i>IMV</i>	<i>Invasive mechanical ventilation</i>
<i>IN</i>	<i>Integrase protein</i>
<i>ISTH</i>	<i>International Society of Thrombosis and Haemostasis</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>LDH</i>	<i>Lactate dehydrogenase</i>
<i>LF</i>	<i>Lactoferrin</i>
<i>LMWH</i>	<i>Low molecular weight heparin</i>
<i>LNP</i>	<i>Lipid nanoparticle</i>
<i>LRT</i>	<i>Lower respiratory tract</i>
<i>MERS</i>	<i>Middle East respiratory syndrome</i>
<i>NIH</i>	<i>National Institutes of Health</i>
<i>NPV</i>	<i>Negative predictive value</i>
<i>NSP</i>	<i>Non-structural proteins</i>
<i>Nt</i>	<i>Nucleotide</i>
<i>ORFs</i>	<i>Open reading frames</i>
<i>PCT</i>	<i>Procalcitonin</i>
<i>PLACID Trial</i>	<i>Parallel-arm phase II multicenter randomized controlled trial</i>
<i>PPV</i>	<i>Positive predictive value</i>
<i>RAAS</i>	<i>Renin-angiotensin-aldosterone system</i>
<i>RBD</i>	<i>Receptor Binding Domain</i>
<i>RdRp</i>	<i>RNA dependent RNA polymerase</i>
<i>ROC</i>	<i>Receiver operator curve</i>
<i>RT-PCR</i>	<i>Reverse transcription - polymerase chain reaction</i>
<i>SaO₂</i>	<i>Oxygen saturation</i>
<i>SARS-COV-2</i>	<i>Severe acute respiratory syndrome coronavirus 2</i>
<i>sHLH</i>	<i>Secondary haemophagocytic lymphohistiocytosis</i>
<i>SPSS</i>	<i>Statistical Package for Social Science (SPSS)</i>
<i>TCZ</i>	<i>Tocilizumab</i>
<i>TMPRSS2</i>	<i>Transmembrane serine protease type 2</i>
<i>TNF</i>	<i>Tumor-necrosis factor</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>UAE</i>	<i>United Arab Emirates</i>
<i>URT</i>	<i>Upper respiratory tract</i>
<i>VIPIT</i>	<i>Vaccine induced prothrombotic immune thrombocytopenia</i>
<i>VTE</i>	<i>Venous thromboembolism</i>
<i>WHO</i>	<i>World Health Organization</i>